Immunodeficiency disorders linked to cytoskeleton defects are rare and complex, often presenting with diverse clinical ...

The variants of ARPC1B described in the literature are displayed, with the red-highlighted variant indicating the one identified in our patient. (B) The variant identified in our patient is ...

Connect Biopharma (CNTB) announced the online publication of results from the global Phase 2 trial of rademikibart in patients with ...

Researchers have found in a new study that Children with a history of severe bronchiolitis in infancy who had low serum 25-hydroxyvitamin D (< 20 ng/mL) at age 3 had a higher risk of ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...

Cycle Pharmaceuticals Limited (Cycle) is pleased to announce that Cycle Vita is now available with BAFIERTAM, expanding its patient support services in MS, following the acquisition of Banner Life ...

AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...